Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 1
| rilzabrutinib | Rilzabrutinib is a selective, covalent, reversible inhibitor of BTK, with a tailored residence time at BTK to reduce off-target effects. In ITP, rilzabrutinib mediates its therapeutic effect through multi-immune modulation by inhibiting B cell activation, interruption of FcgammaR mediated phagocytosis, and potentially amelioration of chronic inflammation associated with ITP. |
|








Citing DrugCentral © 2026.
License